Actively Recruiting
Study of LY4005130 Versus Placebo Administered Intravenously to Adults with Non-Segmental Vitiligo Evaluating Safety and Efficacy Over 24 Weeks
Led by Eli Lilly and Company · Updated on 2026-11-04
66
Participants Needed
35
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating LY4005130, an intravenous drug, to see how well it is tolerated and what side effects may occur in adults with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled study compares LY4005130 to a placebo over about 48 weeks, including screening. Participants must have NSV diagnosed for at least 3 months with specific body surface area involvement. Participants receive either LY4005130 or placebo intravenously during the treatment period. The study includes a 24-week treatment phase where the drug or placebo is administered, and blood tests are done to understand how the body processes the drug and how it affects the skin condition. The study drug is given through the vein in the arm. During the study, participants will have assessments including blood tests, skin evaluations using Vitiligo Area Scoring Indexes F-VASI and T-VASI, and skin biopsies to measure gene expression changes. Researchers will monitor safety, drug levels in the blood, and treatment effects up to 48 weeks. The main outcome is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.
CONDITIONS
Brief Title
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here